Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults

Primary Immune Thrombocytopenia (ITP) Clinical Trial

Official title:

A Multicenter, Randomized, Open-label Study To Compare The Efficacy And Safety Of Eltrombopag Combining Rituximab With Eltrombopag In Adult ITP Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04518475
• Other study ID #: IHBDH-IIT2020014
• Status: Recruiting
• Phase: Phase 4
• Start date: August 10, 2020
• Est. completion date: August 10, 2022

Study information

• Verified date: August 2020
• Source: Institute of Hematology & Blood Diseases Hospital
• Contact: Lei Zhang
• Phone: +86 13502118379
• Email: zhanglei1[@]ihcams.ac.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This multicenter randomized, open-label study aimed to compare the efficacy and safety of eltrombopag combining rituximab with eltrombopag in China adult ITP patients .This study was be conducted in adult ITP patients who had not responded to or had relapsed after previous treatment of ITP, including first line therapy and /or splenectomy.

Description:

The primary objective of this study was to evaluate the efficacy and safety of eltrombopag combining rituximab treating previously treated ITP patients compared to eltrombopag. The secondary objective was to evaluate the efficacy of eltrombopag combining rituximab in ITP patients with positive autoantibody compared to eltrombopag .In addition, health-related quality of life (HRQoL) measure was assessed in all participants.

224 eligible subjects were randomized to either eltrombopag combining rituximab or eltrombopag treatment in 1:1 ratio. 112 enrolled patients are randomly picked up to take eltrombopag combining with rituximab at the indicated dose. 112 enrolled patients are randomly picked up to take eltrombopag at the indicated dose.

The initial dose of eltrombopag administration was an oral 75 mg once daily in all participants .The dose of eltrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24.

Subjects in eltrombopag combining rituximab treatment group received single dose infusion of rituximab 375 mg/m(2) within 14 days after enrollment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 224
• Est. completion date: August 10, 2022
• Est. primary completion date: February 10, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Signed written informed consent

2. Age from 18 to 60 years old

3. Diagnosed with ITP and have a platelet count of <30 ×10^9/L on Day 1 (or within 48 hours prior to dosing on Day 1).

4. Patients who have no response or relapsed after splenectomy(at least more than 6 months). Or patients who have not been splenectomised and have either not responded to one or more prior therapies, or who have relapsed prior therapy.

5. Subjects treated with previous therapy(including but not limited to corticosteroid, azathioprine, danazol, cyclosporin A, mycophenolate mofetil) must have been completed prior to randomization, or must not be increasing a dose after enrollment.

6. No pre-existing cardiac disease within the last 3 months. No arrhythmia known to increase the risk of thrombolic events (e.g. atrial fibrillation), or patients with a Corrected QT interval (QTc) >450msec or QTc >480 for patients with a Bundle Branch Block.

7. No pre-existing infection within the last 1 months(including but not limited to pulmonary infection)

8. Laboratory tests for coagulation function showed that prothrombin time (PT/INR) and activated partial thromboplastin time (APTT) no exceed normal by more than 20%. No history of clotting disorder, other than ITP.

9. White blood cell count, neutrophil absolute value, hemoglobin, within the reference range, with the following exceptions:

• Hemoglobin: females and males 10.0 g/dl are eligible for inclusion,

• Absolute neutrophil count (ANC) =1500/µL (1.5×109/L) is required for inclusion

10. The following blood chemistry test result no exceed normal by more than 20%:alanine aminotransferase, aspartate aminotransferase, total bilirubin, creatinine,serum albumin must not be below the lower limit of normal (LLN) by more than 10%.

11. Subject is non-childbearing potential of childbearing potential and use acceptable methods of contraception throughout the study.

12. Subjects fully understand and are able to comply with the requirements of the research protocol and are willing to complete the study as planned.

Exclusion Criteria:

1. Patients with any prior history of arterial or venous thrombosis, and with following risk factors: cancer, Factor V Leiden, ATIII deficiency, antiphospholipid syndrome.

2. Pregnant or lactating women;

3. Subjects is currently receiving treatment with another study medication.

4. Any laboratory or clinical evidence for HIV infection.

5. Any clinical history for hepatitis C infection; chronic hepatitis B infection; or any evidence for active hepatitis at the time of subject screening. Laboratory test shows positive serology for Hepatitis C or Hepatitis B (HB). In addition, if negative for HBsAg but HBcAb positive (regardless of HBsAb status), a HB DNA test will be performed and if positive the subject will be excluded.

6. History of platelet aggregation that prevents reliable measurement of platelet counts.

7. Any clinically relevant abnormality, other than ITP,which in the opinion of the investigator makes the subject unsuitable for participation in the study.

Related Conditions & MeSH terms

• Primary Immune Thrombocytopenia (ITP)
• Purpura, Thrombocytopenic, Idiopathic
• Thrombocytopenia

Intervention

Drug:
• eltrombopag combining rituximab
After enrollment,all subjects receive eltrombopag treatment,the initial dose of eltrombopag administration was an oral 75 mg once daily.Complete blood count including platelet count was done once a week.The dose of eltrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count >250×10^9/L, the eltrombopag will stop until the platelet count <30×10^9/L. All subjects receive single dose infusion of rituximab 375 mg/m(2) within 14 days after enrollment. Efficacy and safety will be evaluated at Week 4, Week 8, and Week 12.
• eltrombopag
After enrollment,all subjects receive eltrombopag treatment,the initial dose of eltrombopag administration was an oral 75 mg once daily.Complete blood count including platelet count was done once a week.The dose of eltrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count >250×10^9/L, the eltrombopag will stop until the platelet count <30×10^9/L. Efficacy and safety will be evaluated at Week 4, Week 8, and Week 12.

Locations

Country	Name	City	State
China	Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College	Tianjin

Sponsors (6)

Lead Sponsor	Collaborator
Institute of Hematology & Blood Diseases Hospital	Henan Cancer Hospital, Nantong University, The First Affiliated Hospital of Xiamen University, The Second Affiliated Hospital of Kunming Medical University, Tianjin Medical University Second Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Treatment response	Number of participants achieving a platelet count >=30×10^9/L and at least doubling of the baseline count at Week 4, Week 8, and Week 12 .	From the start of study treatment (Day 1) up to the end of week 12.
Secondary	Drug efficacy	Number of participants achieving a platelet count >=30×10^9/L at week 4, week 8, and week 12 in ITP patients with positive autoantibody	From the start of study treatment (Day 1) up to the end of week 4, week 8 and week 12.
Secondary	Long-term treatment response	Number of participants achieving a platelet count >=30×10^9/L at week 16, week 20, and week 24.	From the start of study treatment (Day 1) up to the end of week 16, week 20 and week 24
Secondary	Time to Response	Time to response is defined as time from the start of treatment to the first time of achieving a platelet count >=30×10^9/L and at least doubling of the baseline count during the whole 24 weeks.	From the start of study treatment (Day 1) up to the end of week 24
Secondary	Duration of response	Total duration of time a participant had a platelet count >=30×10^9/L	From the start of study treatment (Day 1) up to the end of week 24.
Secondary	Evaluation of effectiveness	Number of participants that reduced or discontinued baseline concomitant ITP medications during the whole 24 weeks.	From the start of study treatment (Day 1) up to the end of week 24.
Secondary	Number of participants with clinically significant bleeding as assessed using the world health organization (WHO) bleeding scale.	The WHO Bleeding Scale is a measure of bleeding severity with the following grades: grade 0 = no bleeding, grade 1= petechiae, grade 2= mild blood loss, grade 3 = gross blood loss, and grade 4 = debilitating blood loss.	From the start of study treatment (Day 1) up to the end of week 24.
Secondary	Immune Thrombocytopenia Patient Assessment Questionnaire (ITP-PAQ)	In all participants ,use ITP-PAQ to assess the HRQoL before and after treatment.	From the start of study treatment (Day 1) up to the end of week 24.
Secondary	Functional Assessment of Chronic Illness Therapy fatigue subscale (FACIT-F)	In all participants ,use FACIT-F to assess the HRQoL before and after treatment.	From the start of study treatment (Day 1) up to the end of week 24.
Secondary	Number of Participants with side effects of the drugs	Side effects of the drugs included fever, headache, serum disease,hypotension, rashes, infection liver injury, hypokalaemia, etc.	From the start of study treatment (Day 1) up to the end of week 24.